| Barchart Demo Center |
$5,68
+0,13 (+2,34%)
en date du mai 31, 2024
en date du mai 31, 2024
| Dernière | 5,68 |
|---|---|
| Variation | +0,13 (+2,34%) |
| Ouverture | 5,57 |
| Clôture précédente | 5,55 |
| Écart (actuel) |
5,51
5,94
|
| Écart 52 semaines |
2,68
8,22
|
| Volume | 385 800 |
| Volume Moyen | 357 410 |
| Secteur | SIC-2834 Pharmaceutical Preparations |
Perfomance Comparison
| Nom | Aujourd'hui | 3-mois | 1 an |
|---|---|---|---|
| CAPR |
 +2,34% |
 -17,08% |
+25,94% |
| DJIA |
 +1,51% |
 -2,09% |
+16,90% |
| S&P 500 |
+0,80% |
+1,01% |
+25,49% |
Statistiques clef
| BPA Annuel | -0,87 |
|---|---|
| Rendement dividendes | 0,00% |
| Rapport Prix/Bénéfices | N/A |
| Market Capitalization, $K | 178 140 |
| Alpha pondéré | +34,88 |
| Écart-type | +0,62 |
| Marge d'exploitation | -89,72% |
| Beta | 4,06 |
Taux de croissance
| Cette année | +16,16% | |||
| 1 An(s) | +24,84% | |||
| 3 An(s) | +47,15% | |||
| 5 An(s) | +77,50% | |||
| 10 An(s) | -88,17% |
Opinion
| Vendre | Conserver | Acheter |
Articles récents
Capricor: Q1 Earnings Snapshot
AP - Mon May 13, 03:17PM CDT
Capricor: Q1 Earnings Snapshot(version intégrale)
CAPR: 5,68 (+0,13)
Capricor Therapeutics Reports First Quarter 2024
GlobeNewswire - Mon May 13, 03:05PM CDT
–Phase 3, HOPE-3 Trial (Cohort A) of CAP-1002 in Duchenne Muscular Dystrophy Fully Enrolled; On Track to Report Top-Line Data in Q4 2024– –Positive Type-B...(version intégrale)
CAPR: 5,68 (+0,13)
Capricor Therapeutics to Present Exosome Platform
GlobeNewswire - Thu May 09, 08:15AM CDT
-Preclinical findings show exosome-based therapeutic approach for the treatment of arginase-1 deficiency (ARG1-D)- -Presentation to be featured in an oral...(version intégrale)
CAPR: 5,68 (+0,13)
Capricor Therapeutics to Present at Upcoming
GlobeNewswire - Wed May 08, 08:00AM CDT
SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and...(version intégrale)
CAPR: 5,68 (+0,13)
Capricor Therapeutics Announces Positive Type-B
GlobeNewswire - Wed Apr 24, 08:00AM CDT
-Company Aligned with FDA on Demonstration of Non-Clinical Comparability; Allowing for Immediate Use of San Diego Manufacturing Facility-(version intégrale)
CAPR: 5,68 (+0,13)